作者
Sodiomon B Sirima, Benjamin Mordmüller, Paul Milligan, Ulysse Ateba Ngoa, Fred Kironde, Frank Atuguba, Alfred B Tiono, Saadou Issifou, Mark Kaddumukasa, Oscar Bangre, Clare Flach, Michael Christiansen, Peter Bang, Roma Chilengi, Søren Jepsen, Peter G Kremsner, Michael Theisen, Alphonse Ouédraogo, Désiré Kargougou, Issa Nébié, Siaka Débé, Amidou Diarra, Edith Bougouma, Aurore B Hounkpatin, Ayola Akim Adegnika, Bertrand Lell, Fanny Joanny, Yabo Josiane Honkpehedji, Jean Claude Dejon Agobe, Meral Esen, Anthony Ajua, Victor Asoala, Thomas Anyorigiya, Nana Akosua Ansah, William Buwembo, Edison Mworozi, Musa Sekikubo, Ismaela Abubakar, Kalifa Bojang, Ramadhani Noor, Brenda Okech, Dawit A Ejigu
发表日期
2016/8/31
期刊
Vaccine
卷号
34
期号
38
页码范围
4536-4542
出版商
Elsevier
简介
Background
GMZ2 is a recombinant protein malaria vaccine, comprising two blood-stage antigens of Plasmodium falciparum, glutamate-rich protein and merozoite surface protein 3. We assessed efficacy of GMZ2 in children in Burkina Faso, Gabon, Ghana and Uganda.
Methods
Children 12–60 months old were randomized to receive three injections of either 100 μg GMZ2 adjuvanted with aluminum hydroxide or a control vaccine (rabies) four weeks apart and were followed up for six months to measure the incidence of malaria defined as fever or history of fever and a parasite density ⩾5000/μL.
Results
A cohort of 1849 children were randomized, 1735 received three doses of vaccine (868 GMZ2, 867 control-vaccine). There were 641 malaria episodes in the GMZ2/Alum group and 720 in the control group. In the ATP analysis, vaccine efficacy (VE), adjusted for age and site was 14% (95% confidence interval [CI]: 3.6 …
学术搜索中的文章
SB Sirima, B Mordmüller, P Milligan, UA Ngoa… - Vaccine, 2016
